Durable complete response with chemo-immuno-radiotherapy for metastatic cervical cancer progressing under immunotherapy: a case series
This case series suggests that chemo-immuno-radiotherapy with EBRT may represent a salvage treatment for patients who develop secondary loco-regional resistance to immunotherapy, as long as there is remission of the metastatic sites. Given the low response rate to chemotherapy in metastatic cervical cancer patients resistant to pembrolizumab, chemo-radiotherapy while pursuing immunotherapy should be investigated in highly selected patients with oligo-metastasis progression.
Authors
- Sana Intidhar Labidi‐Galy (ORCID: https://orcid.org/0000-0002-0824-3475)
- Patrick Petignat (ORCID: https://orcid.org/0000-0002-6835-533X)
- Manuela Undurraga (ORCID: https://orcid.org/0000-0003-3345-8950)
- Melpomeni Kountouri
- Nathalie Baudoux
- Thomas Westerhoff
Institutions
- University of Geneva (CH)
- Hôpital Beau-Séjour (CH)
- Réseau Fribourgeois de Santé Mentale (CH)
- Swiss Cancer Center Léman (CH)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.gore.2025.101967
- Citations
- 1
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.06